Eden Research plc Director/PDMR Shareholding (7385D)
June 28 2019 - 1:01AM
UK Regulatory
TIDMEDEN
RNS Number : 7385D
Eden Research plc
28 June 2019
28 June 2019
Eden Research plc
("Eden" or "Company)
Director/PDMR Shareholding
Eden Research plc (AIM: EDEN), the AIM listed company that
develops and supplies breakthrough biopesticide products and
natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries,
announces that Lykele van der Broek, Chairman, has purchased
358,500 ordinary shares of 1 pence each in the Company ("Ordinary
Shares") at an average price of 10.94 pence per Ordinary Share.
Following the transaction outlined above, Mr van der Broek is
interested in 358,500 Ordinary Shares representing 0.17 per cent.
of the Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details of the
PDMR dealing set out above.
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Mr Lykele van der Broek
------------------------------------------------------- ------------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------------------------------
a) Position/status Chairman
------------------------------------------------------- ------------------------------------------------------
b) Initial notification /Amendment Initial notification
------------------------------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---------------------------------------------------------------------------------------------------------------
a) Name Eden Research plc
------------------------------------------------------- ------------------------------------------------------
b) LEI 213800ZWTYTVQQSM3J85
------------------------------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Ordinary shares of 1 pence each in the Company
instrument ("Ordinary Shares")
Identification code GB0001646941
------------------------------------------------------- ------------------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------------------------- ------------------------------------------------------
Price(s) - pence Volume(s) - Ordinary
per share Shares
10.5 40,000
c) Price(s) and volume(s) 10.47 40,000
10.75 40,000
10.737 100,000
11.41 138,500
---------------------
------------------------------------------------------- ------------------------------------------------------
d) Aggregated information
- Aggregated volume
358,500 Ordinary Shares
- Price
10.94 pence per share
------------------------------------------------------- ------------------------------------------------------
e) Date of the transaction 27/6/2019
------------------------------------------------------- ------------------------------------------------------
f) Place of the transaction LSE, AIM Market (XLON)
------------------------------------------------------- ------------------------------------------------------
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Shore Capital (Nomad) 020 7408 4090
Stephane Auton / Patrick Castle
Powerscourt (Financial PR) 020 7250 1446
Nick Dibden eden@powerscourt-group.com
Jana Tsiligiannis
Notes:
Eden Research is a technology development and commercialisation
company with intellectual property and expertise in encapsulation,
terpenes and environmentally friendly technologies to provide
naturally occurring solutions for the global agrochemicals, animal
health, and consumer products industries.
Eden's encapsulation technology harnesses the biocidal efficacy
of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. The technology uses
yeast cells that are a by-product of numerous commercial production
processes to deliver a slow release of natural compounds for
agricultural and non-agricultural uses. Terpenes are already widely
used in the food flavouring, cosmetics and pharmaceutical
industries.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Eden's platform encapsulation technology provides a
unique, environmentally friendly solution to these problems and
enables terpenes to be used as effective, low-risk
agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP13m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, 3AEY, were approved as new ingredients for use
in plant protection products. This represented a major milestone in
the commercialisation of Eden's technology and is a significant
accomplishment for any company. To illustrate this point, one
should note that in all of 2013, Eden's approvals represented 3 of
only 10 new active ingredients approved by the EC.
3AEY has been authorised for sale in Kenya, Malta, Greece,
Bulgaria, Spain, Italy, France, Cyprus, Albania, Portugal and
Macedonia.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSELFUWFUSELM
(END) Dow Jones Newswires
June 28, 2019 02:01 ET (06:01 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024